Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?

Authors Németh B, Péter I, Boncz I, Jagicza A, Kiss I, Csergő Á, Kőszegi T, Kustán P, Horváth IG, Ajtay Z

Received 10 December 2018

Accepted for publication 25 April 2019

Published 5 July 2019 Volume 2019:15 Pages 831—837


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Balázs Németh,1,2 Iván Péter,1 Imre Boncz,1 Anna Jagicza,1 István Kiss,2 Ágnes Csergő,2 Tamás Kőszegi,3,4 Péter Kustán,3,4 Iván G Horváth,5 Zénó Ajtay1,5

1Dermatology Unit, Zsigmondy Vilmos SPA Hospital, Harkány, Hungary; 2Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary; 3Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary; 4János Szentágothai Research Centre, University of Pécs, Pécs, Hungary; 5Heart Institute, Medical School, University of Pécs, Pécs, Hungary

Purpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients.
Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m2,), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK®2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index.
Results: One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio.
Conclusion: There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.

Keywords: psoriasis, orosomucoid, oxidative stress, C-reactive protein, biomarker, cardiovascular risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]